Clinical trials have demonstrated the remarkable efficacy of PD-1/PD-L1 inhibitors in MSI-H/dMMR CRC, with durable responses and improved overall survival compared to standard chemotherapy. This evidence concerns the gene PDCD1 and colorectal carcinoma.